Sugi Predict

Sugi Predict / Compounds / SCHEMBL7011009

SCHEMBL7011009

SCHEMBL7011009

Cc1[nH]c(=O)n(-c2c[nH]c3ccccc23)c1-c1c[nH]c2ccccc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SIRT2 Q8IXJ6 3/20 0.47
▸ SIRT1 Q96EB6 1/20 0.47
▸ TDO2 P48775 1/20 0.43
▸ CCNE2 O96020 2/20 0.43
▸ CDK4 P11802 2/20 0.43
▸ PRKACA P17612 2/20 0.43
▸ PRKACG P22612 2/20 0.43
▸ PRKACB P22694 2/20 0.43
▸ CCND1 P24385 2/20 0.43
▸ CCNE1 P24864 2/20 0.43
▸ CDK2 P24941 2/20 0.43
▸ PRKCB P05771 2/20 0.43
▸ PRKD3 O94806 1/20 0.43
▸ CCNB2 O95067 1/20 0.43
▸ ABL1 P00519 1/20 0.43
▸ PRKCG P05129 1/20 0.43
▸ CDK1 P06493 1/20 0.43
▸ PIM1 P11309 1/20 0.43
▸ CCNB1 P14635 1/20 0.43
▸ PRKCA P17252 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7010190 0.82 NT5E (0.45) SIRT2SIRT1TDO2CCNE2CDK4
SCHEMBL7006894 0.81 SIRT2 (0.41) SIRT2SIRT1TDO2CCNE2CDK4
SCHEMBL7012175 0.78 RPS6KB1 (0.59) SIRT2SIRT1CCNE2CDK4PRKACA
SCHEMBL7006065 0.78 PKM (0.39) SIRT2SIRT1CCNE2CDK4PRKACA
SCHEMBL7010672 0.77 SIRT2 (0.48) SIRT2SIRT1TDO2CCNE2CDK4
SCHEMBL8520286 0.75 HSP90AA1 (0.54) SIRT2SIRT1MEN1KMT2ALMNA
SCHEMBL6976408 0.69 MEN1 (0.40) SIRT2SIRT1CCNE2CDK4PRKACA
SCHEMBL6984020 0.69 CDK4 (0.48) SIRT2SIRT1CCNE2CDK4PRKACA
SCHEMBL7820421 0.69 PDE9A (0.40) CDK4MEN1KMT2ALMNAKDM4E
SCHEMBL7005539 0.67 CDK4 (0.55) SIRT2SIRT1CCNE2CDK4PRKACA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1042317-B1 Indole derivatives as PKC-inhiboitors ASTRAZENECA AB (SE) 2003-05-14 — — EP claimed
US-20030134886-A1 Pharmaceutically active compounds ASTRAZENECA AB, A SWEDISH CORPORATION 2003-07-17 — — US disclosed
EP-1042317-B1 Indole derivatives as PKC-inhiboitors ASTRAZENECA AB (SE) 2003-05-14 — — EP disclosed
US-6492409-B1 SUCH AS 5-(1-(3-AMINOPROPYL)-3-INDOLYL)-1-(3-INDOLYL)-1,3-DIHYDROIMIDAZOL-2-ONE; PROTEIN KINASE C INHIBITORS; HIGH SOLUBILITY; REDUCED COLOR; TREATING INFLAMMATORY AND/OR IMMUNOLOGICAL DISORDERS ASTRAZENECA AB (SE) 2002-12-10 — — US disclosed
EP-1192150-A1 NEW PHARMACEUTICALLY ACTIVE COMPOUNDS AstraZeneca AB (SE) 2002-04-03 — — EP disclosed
US-6337342-B1 ARYLIMIDAZOLONE DERIVATIVES ASTRAZENECA AB (SE) 2002-01-08 — — US disclosed
WO-2000078750-A1 NEW PHARMACEUTICALLY ACTIVE COMPOUNDS ASTRAZENECA AB (SE) 2000-12-28 — — WO disclosed
EP-1042317-A1 NEW PHARMACEUTICALLY ACTIVE COMPOUNDS AstraZeneca AB (SE) 2000-10-11 — — EP disclosed
WO-1999032483-A1 NEW PHARMACEUTICALLY ACTIVE COMPOUNDS ASTRAZENECA AB (SE) 1999-07-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030134886-A1 Pharmaceutically active compounds HTR3C, HTR6, CNR1 SIRT2 1112/4885SIRT1 713/4885TDO2 187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.